We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEvoke Pharma Inc

Evoke Pharma Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-03-05T21:13:23.223196Z
Market Cap
3.74M

Momentum Score

…

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.40
Low
1.96
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
5.18M
Revenue Per Share
1.55
Gross Profit TTM
2.14M
Debt / Equity
-1.94
ROE
-1035.44%
Net Debt
0.26M
ROCE
-193.07%
Diluted EPS TTM
-1.84

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -8.22M -8.54M -13.15M -7.13M -7.57M
Net income -8.16M -9.03M -13.26M -7.10M -7.57M
Selling general administrative 9.62M 8.85M 6.43M 3.74M 3.92M
Gross profit 2.14M 1.29M -0.06M - 0.00M
Ebit -7.79M -8.15M -13.05M -7.13M -8.91M
Ebitda -7.72M -8.14M -13.04M -7.15M -8.45M
Depreciation and amortization 0.06M 0.01M 0.01M - 0.46M
Non operating income net other - - - - 0.43M
Operating income -7.79M -8.15M -13.05M -7.15M -8.01M
Other operating expenses 10.29M 9.77M 13.07M 7.15M 8.01M
Interest expense 0.50M 0.50M 0.11M 0.03M 0.02M
Interest income 0.06M 0.01M 0.01M 0.03M 0.02M
Net interest income -0.44M -0.49M -0.11M 0.03M 0.02M
Income tax expense -0.06M 0.49M 0.11M -0.03M -0.91M
Total revenue 2.51M 1.62M 0.02M 0.00M 0.00M
Total operating expenses 9.92M 9.44M 12.98M 7.15M 8.01M
Cost of revenue 0.37M 0.33M 0.09M - 0.00M
Total other income expense net -0.44M -0.39M -0.11M 0.03M 0.43M
Net income from continuing ops -8.22M -8.54M -13.15M -7.13M -7.57M
Net income applicable to common shares -8.22M -8.54M -13.15M -7.13M -7.57M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 7.07M 11.85M 10.57M 9.43M 6.40M
Other current assets 0.93M 0.01M 0.01M 0.03M 0.58M
Total liab 9.65M 7.77M 7.02M 12.65M 2.02M
Total stockholder equity -2.58M 4.08M 3.56M -3.21M 4.38M
Other current liab 1.32M 0.59M 0.52M 6.02M 1.88M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -123.44M -115.65M -107.42M -98.89M -85.73M
Other liab - 1.11M 0.61M 0.11M -
Other assets - - - 0.15M 0.01M
Cash 4.74M 9.84M 9.14M 8.07M 5.66M
Total current liabilities 3.04M 1.65M 1.41M 7.54M 2.02M
Current deferred revenue -5.00M - - - -
Net debt 0.26M -4.71M -4.13M -2.82M -5.53M
Short term debt 5.00M 0.13M 0.01M 0.25M 0.14M
Short long term debt 5.00M - - 0.10M -
Short long term debt total 5.00M 5.13M 5.01M 5.25M 0.14M
Other stockholder equity 120.86M 119.73M 110.97M 95.67M 90.11M
Property plant equipment - 0.13M 0.01M 0.14M 0.14M
Total current assets 6.83M 11.72M 10.56M 9.28M 6.25M
Net tangible assets - 4.08M 3.56M -3.21M 4.38M
Net receivables 0.67M 0.62M 0.30M 0.02M -
Long term debt 5.00M 5.00M 5.00M 5.00M -
Inventory 0.48M 0.29M 0.19M 0.24M -
Accounts payable 1.71M 0.93M 0.87M 1.27M 1.88M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -98.89M -85.73M
Non currrent assets other 0.24M - - 0.01M 0.01M
Non current assets total 0.24M 0.13M 0.01M 0.15M 0.15M
Capital lease obligations 0.00M 0.13M 0.01M 0.14M 0.14M
Long term debt total - - - 5.00M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Change to liabilities 0.06M -0.53M 0.42M 0.11M -0.44M
Net borrowings - - 5.10M 5.10M 5.10M
Total cash from financing activities 7.29M 13.43M 9.04M 6.11M 4.62M
Change to operating activities 0.51M -4.84M 4.72M -0.12M -0.08M
Net income -8.22M -8.54M -13.15M -7.13M -7.57M
Change in cash 0.70M 1.08M 2.41M 0.34M -2.36M
Begin period cash flow 9.14M 8.07M 5.66M 5.32M 7.68M
End period cash flow 9.84M 9.14M 8.07M 5.66M 5.32M
Total cash from operating activities -6.60M -12.35M -6.63M -5.76M -6.98M
Issuance of capital stock 7.44M 13.38M 3.60M 6.11M 4.62M
Change to inventory -0.10M 0.02M -0.24M -0.24M -0.24M
Change to account receivables -0.33M -0.27M 4.60M -0.27M -0.27M
Sale purchase of stock - - 0.12M 6.11M 4.62M
Other cashflows from financing activities -0.15M 0.05M 5.32M -1.31M -
Change to netincome 1.50M 1.80M 1.74M 1.37M 1.11M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Cash flows other operating - - 4.60M -0.12M -0.08M
Cash and cash equivalents changes - - 2.41M 0.34M -2.36M
Change in working capital 0.13M -5.62M 4.90M -0.01M -0.52M
Stock based compensation 1.46M 1.88M 1.63M 1.37M 1.54M
Other non cash items 0.04M -0.08M 7.38M -0.23M -0.43M
Free cash flow -6.60M -12.35M -6.63M -5.76M -6.98M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR		 -0.74
2.19%		 33.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.34
1.66%		 21.18 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Evoke Pharma Inc

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

420 Stevens Avenue, Solana Beach, CA, United States, 92075

858 345 1494

https://evokepharma.com

4

Name Title Year Born
Mr. David A. Gonyer Co-Founder, CEO, Pres & Director 1964
Mr. Matthew J. D'Onofrio Co-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec. 1970
Dr. Marilyn R. Carlson Chief Medical Officer 1948
Mr. Christopher Quesenberry Chief Commercial Officer - Gimoti (TM) NA
Mr. Matthew J. D'Onofrio MBA Co-Founder, President, CEO, COO, Secretary, Treasurer & Director 1970
Dr. Marilyn R. Carlson D.M.D., M.D., RAC. Chief Medical Officer 1948

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…